Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

The Next Generation of ADPKD Therapies

The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more
What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more
CAR-T Therapy Explained: A Plain-English Guide

CAR-T Therapy Explained: A Plain-English Guide

CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...

read more
Weekly News Roundup | 17 August 2026

Weekly News Roundup | 17 August 2026

Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

read more
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...

read more
Clinical Trials Roundup | 14 Aug 2026

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

read more
The Next Generation of ADPKD Therapies

The Next Generation of ADPKD Therapies

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the leading monogenic cause of kidney failure worldwide, affecting an estimated 12.5 million people globally. For nearly a decade, tolvaptan — a vasopressin V2...

read more
What Trauma Taught Me That Medical School Never Did

What Trauma Taught Me That Medical School Never Did

Medical school taught me how to diagnose disease, interpret imaging, manage pain, and treat injury. It taught me remarkably little about what chronic trauma does to the body. Like many physicians, I was trained to think of trauma primarily as a psychological injury,...

read more
CAR-T Therapy Explained: A Plain-English Guide

CAR-T Therapy Explained: A Plain-English Guide

CAR-T therapy is one of the most discussed cancer treatments of the past decade, and one of the most widely misunderstood. The name is an acronym. The science involves genetic engineering. The price runs to hundreds of thousands of pounds per patient. This guide...

read more
Weekly News Roundup | 17 August 2026

Weekly News Roundup | 17 August 2026

Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...

read more
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

LSD Anxiety Data: Definium Hits All Phase 3 Endpoints

Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...

read more
Clinical Trials Roundup | 14 Aug 2026

Clinical Trials Roundup | 14 Aug 2026

Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Kidney Care’s $2.5 Billion Timing Problem

Kidney Care’s $2.5 Billion Timing Problem

Capital is flowing to the wrong point on the disease timeline Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one. Investment has mostly concentrated on...

read more
Beyond Weight Loss: What Emerging GLP-1 Research Reveals

Beyond Weight Loss: What Emerging GLP-1 Research Reveals

For many years, the perception of obesity and metabolic syndrome has largely been framed within the context of lifestyle and individual choices. However, an unprecedented paradigm shift is taking place as researchers gain a more profound insight into the physiological...

read more
GLP-1 Side Effects: What the Evidence Actually Says

GLP-1 Side Effects: What the Evidence Actually Says

An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...

read more

Further News

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

Why Complement Therapeutic Research Requires More Than a Single Assay

Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity,...

AstraZeneca Strategic Equity Investment Puts $2bn Into Summit Therapeutics

AstraZeneca has made a 2 billion US dollar strategic equity investment in Summit Therapeutics. Summit announced the deal through Business Wire on 28 September 2026, after the US market close. The money buys convertible preferred stock. It does not buy a licence to...

When the Model Is Confident and the Patient Is Not

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

China Out-Licensing Deals 2026: The Billion-Dollar Tracker

In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

What EU PFAS and Microplastics Rules Mean for Cosmetics Formulators

Cosmetics regulation rarely makes it onto the radar of pharma, biotech, or medical device professionals. It probably should, at least for the next few years. The European Union is in the middle of building two overlapping restriction regimes, one for PFAS and one for...

Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision

Daiichi Sankyo and Merck withdrew a US small cell lung cancer treatment filing for ifinatamab deruxtecan. LSDN examines the UK access gap.

    Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer

    The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...

    Why Digital Therapeutics Struggle to Enter Clinical Workflows

    The practical barriers between promising digital therapeutic research and routine care, from validation and safety reporting to staff adoption and patient experience. A digital therapeutic can produce encouraging research results, receive regulatory clearance and...

    Weekly News Roundup | 28 September 2026

    Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...

    Multi-Cancer Early Detection Test Divides FDA Advisers

    An FDA advisory panel backed GRAIL’s Galleri multi-cancer early detection test six to four on effectiveness, days after the English trial behind much of the evidence missed its primary endpoint.

      Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal

      Merck’s remigromig met the BRUNELLO endpoint, but the diabetic macular oedema treatment package carries no figures and a retinopathy imbalance.

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.

        See More Articles

        Want to Be Part of the Next Chapter in Life Sciences Media?

         

        LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

         

         

        Don’t wait for the media to pick up your story. Be the media.